Analysis Of The Efficacy And Safety Of The Fixed-Dose Combination Of Tiotropium + Olodaterol In Patients With COPD By Initial Disease Severity

Rationale: Tiotropium (T), a long-acting muscarinic antagonist, and olodaterol (O), a long-acting β2-agonist (both administered once-daily), have been studied as a once-daily fixed-dose combination (FDC). Data from two, large clinical studies demonstrated that T+O FDC significantly improved lung function and symptoms over the monotherapies in patients with moderate to very severe COPD.1 This analysis was conducted to determine whether the effects in lung function observed in the overall population of these studies were seen in subgroups of patients according to initial disease severity. Methods: In total, 5162 p…